Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma

NCT00001337 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00001337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 8, 1993
Completion date
May 24, 2024
Enrollment
348 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large-cell lymphoma, burkitt lymphoma, diffuse large b-cell lymphoma (dlbcl), gray zone lymphoma, primary mediastinal large b-cell lymphoma